This article is more than 5 years old. Information may no longer be current.
VIDEO: Immunotherapies, antibodies show promise in treating lung cancer
Click Here to Manage Email Alerts
The use of nivolumab both as monotherapy and in combination with ipilimumab demonstrates increased safety and efficacy in patients with small cell lung cancer, according to David Spigel, MD, director of the Lung Cancer Research Program at the Sarah Cannon Research Institute.
In this video, Spigel speaks with HemOnc Today about several trials presented at the ASCO Annual Meeting that demonstrate that immunotherapy and antibody therapies have a positive impact in treating patients with lung cancer.
Spigel also highlights results of a phase 1 trial in which patients with progressive small cell lung cancer after previous therapy demonstrated delayed tumor growth and tumor shrinkage when treated with rovalpituzumab tesirine (SC16LD6.5, Stemcentrx).
“It’s not hard to imagine a future where immunotherapy is going to find its way into small cell lung cancer care,” he said.